We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 2

Figure 2. Systemic and local vaccine related reactogenicity for each dose and route of vaccination.. From: Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate.

The number and percent of subjects experiencing one or more local (panel A) or systemic (panel B) reactions is shown for each group after stratification by severity. The most severe reaction experienced by a volunteer determined the stratification into none, moderate, mild or severe categories. No serious or life threatening adverse events were reported.

Jeffrey R. Currier, et al. PLoS One. 2010;5(11):e13983.
2.
Figure 1

Figure 1. Consort clinical trial participant flow diagram (panel A).. From: Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate.

Chronological schematic diagram showing all pre-enrollment, vaccination and blood collection visits for RV158 (panel B). Immunogenicity testing visits 3, 6, 8, 9 and 10 correspond to days 0, 42, 98, 168 and 252 post-vaccination initiation respectively.

Jeffrey R. Currier, et al. PLoS One. 2010;5(11):e13983.
3.
Figure 5

Figure 5. Multifunctional flow cytometry analysis for HIV Env-specific T cells.. From: Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate.

Analysis was based on the cumulative positive cells in all Boolean subsets for all volunteers who were scored as positive by single cytokine analysis in the high-dose (108 pfu) intra-muscular vaccine recipients (Table 5). The legend shows the Pie Chart arcs representing each cytokine (or function). Pie Chart wedges show the relative sizes of the subsets of cells expressing the combination of functions represented in the surrounding Pie chart arcs.

Jeffrey R. Currier, et al. PLoS One. 2010;5(11):e13983.
4.
Figure 4

Figure 4. Cumulative analysis of all qualitative cellular immune response assays.. From: Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate.

The number of positive responders for HIV antigens (Env or Gag) in the 51Cr-release, Elispot, lymphocyte proliferation and whole blood ICS assays was tallied for all groups and compared with the placebo recipients. The figure graphically displays the summed cumulative positive responders for each of the 4 assay platforms. The total number of tests performed in each group is denoted below the dose and route. The top and bottom tables summarize the statistical analyses for Env and Gag respectively.

Jeffrey R. Currier, et al. PLoS One. 2010;5(11):e13983.
5.
Figure 3

Figure 3. Lymphocyte proliferation responses for each dose and route.. From: Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate.

Lymphocyte proliferation responses against recombinant proteins (TH023 gp140 and LAI p24) are shown for all doses and routes of vaccination (panels A and B). HIV whole inactivated virus (WIV) antigens CM235WIV (CRF01_AE vaccine matched isolate) and MNWIV (subtype B heterologous isolate) are shown for all doses and routes of vaccination in panels C and D respectively. The Y-axis represents the LSI (scale = log2) and the dotted line designates an LSI of 5 (cut-off for positive responses). Blue and red circles represent pre- and post-vaccination (day 0 and day 252) samples respectively.

Jeffrey R. Currier, et al. PLoS One. 2010;5(11):e13983.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk